Britain and America have concluded a important bilateral deal that will guarantee zero levies on UK medicine exports entering the American market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that import taxes on these vital exports will remain at zero for a duration of 36 months.
This agreement is in response to recent statements to hike import taxes on patented drug imports, with figures mentioned up to one hundred percent.
"This arrangement between the UK strengthens the global environment for innovative medicines and introduces much-needed equity to American-British medicine commerce," an announcement noted.
Trade Impact
Medicines are one of the the United Kingdom's biggest goods shipped to the America, which is by far the biggest market for leading companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period prior to the third quarter, the UK exported pharmaceutical products totaling £11.1bn to the US. This value represented 17.4% of total UK exports in that timeframe.
"This agreement safeguards jobs, stimulates capital expenditure and facilitates the UK to become a global hub for medical research," a minister remarked.
Detailed UK Commitments
The deal involves several specific changes from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to increase overall NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be restricted at 15%. Previously, refunds were more than 20%.
Industry Background
The pact comes amid a ongoing row between the sector and the ministers over medicine costs and approval rates.
These tensions were heightened by claims that US customers were paying a premium for the identical medicines than people in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been paused or scrapped, while major expansions have been pledged toward American operations.
One official acknowledged that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.
